IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional inf...

Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic suppression among virologically suppressed adults with HIV, according to a study presented...

The “2026 HRS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extraction” provides updated recommendations to guide clinicians in the management o...

Significantly more adolescents had initiated and completed the series by age 13 years among those introduced at 9 to 10 years vs 11 to 12 years.

David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.

TUESDAY, Oct. 27, 2026 (HealthDay News) -- Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic s

The IDSA guidance suggests treating Enterobacterales resistant to ertapenem but susceptible to imipenem or meropenem with a susceptible carbapenem in the absence of carbapenemase production; however, clinical outcomes data are limited.MethodsWe conducted a multicenter prospective cohort study of hospitalized patients with invasive ceftriaxone-resistant Enterobacterales infections, comparing 30-day mortality between ertapenem-susceptible (ETP-S) and ertapenem-resistant (ETP-R) isolates. ETP-S isolates with an ESBL/AmpC phenotype served as the comparator because carbapenems are reliably active against these organisms. Carbapenem susceptibility was confirmed by broth microdilution. Inclusion criteria included: (1) susceptibility to imipenem or meropenem, (2) absence of carbapenemase genes, and (3) >72 hours of definitive therapy with imipenem or meropenem. Inverse probability weighting (IPW) adjusted for baseline differences, and logistic regression estimated odds ratios with 95% confidence intervals.ResultsAmong 374 patients, 238 (64%) were infected with ETP-S and 136 (36%) ETP-R isolates. Baseline characteristics were balanced after IPW. ETP-R infection was associated with higher 30-day mortality (OR 2.24, 95% CI 1.26-3.98, p=0.006). Similarly, 14-day and in-hospital mortality were significantly higher among patients with ETP-R infections. The highest mortality was observed among patients with isolates resistant to two carbapenems (e.g., ertapenem and meropenem). Genomic analyses demonstrated enrichment of porin alterations and more non-carbapenemase β-lactamase genes (e.g., blaCTX-M, blaOXA-10) in ETP-R isolates.ConclusionAmong patients with Enterobacterales bacteremia treated with imipenem or meropenem, ETP-R isolates were associated with higher mortality than ETP-S isolates, challenging current guidance. This likely reflects combined porin loss and increased β-lactamase activity, potentially resulting in partial hydrolysis of higher-order carbapenems despite in vitro susceptibility.

Summary The emphasis on ‘new ways of warfare’ in the Defense of Japan 2026, released on 4 August, indicates Japan’s desire to play a more assertive role. However, the emphasis… Continue reading Assess...

IDSA's COVID-19 management guideline has been updated with a new recommendation on #pemivibart!